Brachy boost therapy should be reserved for unfavorable risk patients

The ASCENDE-RT trial showed that oncological outcomes were improved among both intermediate-risk and high-risk men who were treated with external beam radiation (EBRT) and a brachytherapy boost (LDR-BT) to the prostate and adjuvant androgen deprivation therapy (ADT) (see this link). … READ MORE …

Cancer tissue subtypes and prostate cancer prognosis

A newly published article in JAMA Oncology is asking whether there is a completely different way to look at how to classify prostate cancer tissue types and correlate such classification to responses to treatment using certainly classes of drugs. … READ MORE …

Another journalist writes about HIS diagnosis with Stage IV prostate cancer

Scott Monserud is the sports editor for The Denver Post in Denver, CO. In the first of a series of articles entitled “Help, and Hope: A Cancer Journal” he writes about his own personal experience. Click here to get his tale.

Numbers progressing and time to progression on active surveillance

A new study just published in the World Journal of Urology has provided us with data from the Prostate Cancer Outcomes Registry — Victoria (in Australia) on the progression of men initially managed on active surveillance. … READ MORE …

Kaiser reports on quality of life outcomes after first-line treatment for prostate cancer

Kaiser Permanente maintains a large data registry in  order to assess the quality of outcomes over time among tens of thousands of Kaiser patients, prostate cancer patients included. … READ MORE …

The evolution of evaluation of risk for clinically significant prostate cancer

Whatever one may happen to think about the value of the PSA test, we all know that it is very bad at actually telling a doctor or a patient if that patient is at real risk for clinically significant prostate cancer. So, from that perspective … READ MORE …

Feedback to USPSTF on new, draft recommendations on PSA screening

As many readers will be aware, the U.S. Preventive Services Task Force (USPSTF) recently issued new, draft guidance on the role of testing for risk of prostate cancer, and most particularly on the use of PSA testing in men of 55 years and older. All public comment on the proposed new draft recommendations is due on or before May 8 upcoming. … READ MORE …